Amphista Therapeutics, a biotech focused on the discovery and development of next generation protein degradation therapeutics, has entered into two significant partnerships with pharma giants, Bristol Myers Squibb (BMS) and Merck KGaA. When combined, these deals could bring the company up to US$2.2 B. Both collaborations will leverage Amphista’s Eclipsys platform to develop small molecule protein degraders. Although the indications were not disclosed by BMS, Merck will initially work on three targets in oncology and immunology indications.